Home Featured Page 103

Featured

Latest

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Numinus to Host Q3 2023 Results Conference Call on July 17,...

Psychedelic Research Bulletin: May 2023

Small Pharma Reports Financial Results for the Fiscal Year Ended February...

An Abridged History of Psychedelic Use and Criminalisation

PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic...

BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD...

PT419 – Ketamine-Assisted Therapy for Severe Alcohol Use Disorder

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil...

PT418 – Psychedelic Morning Show #2 with Joe Moore and Anne...

PT417 – Psychedelic Morning Show #1 with Joe Moore and Anne...

EDITOR PICKS

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug...

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Numinus to Host Q3 2023 Results Conference Call on July 17,...

Psychedelic Research Bulletin: May 2023

Small Pharma Reports Financial Results for the Fiscal Year Ended February...

An Abridged History of Psychedelic Use and Criminalisation

PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic...

BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD...

PT419 – Ketamine-Assisted Therapy for Severe Alcohol Use Disorder

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil...

PT418 – Psychedelic Morning Show #2 with Joe Moore and Anne...

PT417 – Psychedelic Morning Show #1 with Joe Moore and Anne...

EDITOR PICKS

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug...

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY